Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05045235
Active, not recruiting Observational

Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk

NCT05045235 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Started
2021-09-01
Last updated
2025-11-19

Condition(s) studied

Iatrogenic EffectPrescriptionFollow-upConsultation

Study summary

The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patient hospitalized in the geriatric medicine department * Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization; * Numerous therapeutic modifications (3 or more); * Drug interaction or introction of a new drug with one or more drug interactions; * Medicinal product with a narrow therapeutic marge drug requiring close monitoring. Exclusion Criteria: * patient non hospitalized in the geriatric medicine department

Primary outcome measure(s)

  • Change of side effect number in ederly with polymedicated drugs — up to 4 years
    Change of side effect number in ederly with polymedicated drugs

Trial sites (1)

FacilityCityRegionStatus
Amiens University Hospital Amiens France

More Centre Hospitalier Universitaire, Amiens trials in France

Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence Recruiting
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection Recruiting
Validation, in a Pediatric Population, of a French Translation of the MEPS/MEPI Score Recruiting
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease Recruiting
Interest of Prior Relaxation on the Recordings of the SomatoSensory Evoked Potentials Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05045235 on ClinicalTrials.gov ↗ ← All trials in France